Drug Profile
Patritumab deruxtecan - Daiichi Sankyo Company
Alternative Names: HER3-DXd; MK-1022; Patritumab-DX-8951 conjugate; U3-1402; U3-1402aLatest Information Update: 14 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co; SCRI Development Innovations; SOLTI Breast Cancer Research Group
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Non-small cell lung cancer
- Phase II Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Phase I/II HER2 positive breast cancer
Most Recent Events
- 21 Mar 2024 Phase-I/II clinical trials in HER2-positive-breast-cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in France (IV) (NCT06298084)
- 21 Mar 2024 Phase-I/II clinical trials in HER2-positive-breast-cancer (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV) (NCT06298084)
- 26 Feb 2024 Phase-II clinical trials in Gastric cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Japan (IV) (NCT06172478)